Cargando…

The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials

Aims: Inflammatory biomarkers may play vital roles in the pathophysiology of diabetes and diabetic cardiorenal complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a potential cardiovascular and renal protective effect in type 2 diabetes. The aim of this meta-analysis was to quantif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Dongmei, Liu, Jieying, Zhong, Ling, Li, Shunhua, Zhou, Liyuan, Zhang, Qian, Li, Ming, Xiao, Xinhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717685/ https://www.ncbi.nlm.nih.gov/pubmed/36467062 http://dx.doi.org/10.3389/fphar.2022.1045235

Ejemplares similares

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
por: Chen, Lu, et al.
Publicado: (2020)

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism
por: Xie, Lingxiang, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors Work as a “Regulator” of Autophagic Activity in Overnutrition Diseases
por: Fukushima, Kazuhiko, et al.
Publicado: (2021)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
por: Norre, Tobias, et al.
Publicado: (2022)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
por: Xue, Genlong, et al.
Publicado: (2022)

Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
por: Wood, Stephen J, et al.
Publicado: (2022)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
por: Cao, Yang, et al.
Publicado: (2022)

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice
por: Wang, Dongmei, et al.
Publicado: (2022)

Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function in vitro
por: Saran, Chitra, et al.
Publicado: (2023)

Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials
por: Hu, Suiyuan, et al.
Publicado: (2022)

Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level
por: van der Hoek, Sjoukje, et al.
Publicado: (2022)

Phloridzin inhibits high K(+)-induced contraction via the inhibition of sodium: glucose cotransporter 1 in rat ileum
por: KANDA, Hidenori, et al.
Publicado: (2017)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
por: Wang, Dongmei, et al.
Publicado: (2022)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
por: Ye, Yangli, et al.
Publicado: (2019)

Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
por: Ren, Changzhen, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
por: Li, Hang-Long, et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties
por: Li, Hung‐Yuan
Publicado: (2020)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis
por: Ren, Bangjiaxin, et al.
Publicado: (2022)

Prescribing Patterns for Sodium-Glucose Cotransporter 2 Inhibitors: A Survey of Nephrologists
por: Singh, Tripti, et al.
Publicado: (2023)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
por: Sasaki, Takashi
Publicado: (2018)

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
por: Grubić Rotkvić, Petra, et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n4kppmalvrq3ilptb1188e7sc7